MarketCap
Xenetic Biosciences XBIO
$ 1.87
-1.06%
Facebook
X
Telegram
Xenetic Biosciences ROE Ratio | XBIO
Annual ROE Ratio Xenetic Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.25 | -65.93 | -42.21 | -48.01 | -30.69 | -89.18 | -74.22 | -73.65 | -25.14 | -335.24 | -189.26 | -136.51 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -25.14 | -335.24 | -95.52 |
Quarterly ROE Ratio Xenetic Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.24 | -52.56 | -52.2 | -56.42 | -54.72 | -37.09 | -46.78 | -49.42 | -38.97 | -25.2 | -30.74 | -38.64 | -39.21 | -32.55 | -39.25 | -44.83 | -39.54 | -30.12 | -92.01 | -93.12 | -91.65 | -79.35 | -131.06 | -77.17 | -77.07 | -67.42 | -85.7 | -54.44 | -64.82 | -57.11 | -72.88 | -75.01 | -74.61 | -56.22 | -71.51 | -351.18 | -352.85 | -332.82 | -413.37 | -415.11 | -156.46 | -134.37 | -164.73 | -110.5 | -132.24 | -95.45 | -96.11 | -87.37 | -68.48 | -40.62 | -40.04 | 74.47 | 132.96 | 157.34 | 157.29 | 51.05 | 13.48 | -0.12 | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 157.34 | -415.11 | -77.32 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adagene
ADAG
|
-49.82 | $ 1.99 | -1.73 % | $ 117 M |  China |
 |
Benitec Biopharma
BNTC
|
-25.73 | $ 9.51 | 10.07 % | $ 443 M |  USA |
 |
Denali Therapeutics
DNLI
|
-50.56 | $ 20.09 | 1.88 % | $ 3.47 B | USA |
 |
Amarin Corporation plc
AMRN
|
-8.45 | $ 11.55 | -0.2 % | $ 4.79 B |  Irlanda |
 |
Editas Medicine
EDIT
|
-586.56 | $ 2.57 | 0.59 % | $ 228 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-34.62 | $ 29.4 | 4.0 % | $ 1.7 B | USA |
 |
Cue Biopharma
CUE
|
-100.64 | $ 18.93 | 5.11 % | $ 1.79 B | USA |
 |
Equillium
EQ
|
-78.32 | $ 1.54 | 15.79 % | $ 88.2 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
19932.98 | $ 1.73 | 4.22 % | $ 98.4 M | USA |
 |
Pliant Therapeutics
PLRX
|
82.39 | $ 0.81 | -0.12 % | $ 49.7 M | USA |
 |
Abeona Therapeutics
ABEO
|
-44.71 | $ 4.18 | 6.78 % | $ 221 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
-9.17 | $ 4.36 | 8.19 % | $ 706 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
31.86 | $ 21.22 | -0.09 % | $ 3.57 B | USA |
 |
PainReform Ltd.
PRFX
|
-58.78 | $ 0.85 | 11.62 % | $ 551 K |  Israel |
 |
Jazz Pharmaceuticals plc
JAZZ
|
-8.25 | $ 235.01 | 3.38 % | $ 14.3 B | Irlanda |
 |
Atossa Therapeutics
ATOS
|
-88.35 | $ 2.14 | 5.94 % | $ 18.4 M | USA |
 |
Liquidia Corporation
LQDA
|
-154.03 | $ 44.53 | 0.08 % | $ 3.83 B | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
-119.12 | - | -7.31 % | $ 49 M | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
-31.81 | - | - | $ 1.77 B | USA |
 |
ADC Therapeutics SA
ADCT
|
76.75 | $ 1.59 | -2.16 % | $ 202 M |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 33.1 | 1.96 % | $ 1.9 B | USA |
 |
Ardelyx
ARDX
|
-37.14 | $ 2.88 | -3.85 % | $ 694 M | USA |
 |
Akebia Therapeutics
AKBA
|
-16.25 | $ 0.39 | -7.57 % | $ 100 M | USA |
 |
Alector
ALEC
|
-466.57 | $ 2.3 | 9.81 % | $ 237 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-391.42 | $ 1.16 | 0.43 % | $ 62.2 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-101.78 | $ 20.13 | 3.5 % | $ 6.31 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-43.75 | $ 3.65 | -0.54 % | $ 699 M |  Canada |
 |
Agenus
AGEN
|
1.14 | $ 7.13 | 10.71 % | $ 212 M | USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 11.89 | 6.83 % | $ 3.55 B | Canada |
 |
Artelo Biosciences
ARTL
|
1012.5 | $ 1.98 | -6.62 % | $ 375 K | USA |
 |
Immatics N.V.
IMTX
|
-40.58 | $ 6.36 | 2.91 % | $ 778 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
-149.4 | $ 1.24 | -2.36 % | $ 391 K | USA |
 |
Aligos Therapeutics
ALGS
|
-45.18 | $ 4.14 | -8.2 % | $ 40.9 M | USA |
 |
Aclaris Therapeutics
ACRS
|
-62.98 | $ 3.9 | 8.03 % | $ 478 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-27.19 | $ 27.98 | 4.29 % | $ 4.25 B | USA |
 |
Cellectar Biosciences
CLRB
|
-255.25 | $ 1.24 | 7.83 % | $ 3.23 M | USA |
|
Larimar Therapeutics
LRMR
|
-212.17 | $ 2.4 | 3.23 % | $ 199 M | USA |
 |
Biofrontera AG
BFRA
|
-176.58 | - | -8.24 % | $ 105 M | Germany |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
-91.72 | - | -6.97 % | $ 657 M | USA |
 |
Capricor Therapeutics
CAPR
|
-34.35 | $ 8.97 | 4.3 % | $ 417 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 28.5 | 3.04 % | $ 1.33 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
7.32 | - | 1.68 % | $ 4.65 B | China |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 3.6 | -1.64 % | $ 385 M | USA |
 |
Jaguar Health
JAGX
|
0.29 | $ 0.4 | -2.16 % | $ 933 K | USA |
 |
Arvinas
ARVN
|
-18.67 | $ 6.41 | -2.14 % | $ 454 M | USA |
 |
Cerus Corporation
CERS
|
-24.33 | $ 2.03 | -4.93 % | $ 387 M | USA |
 |
Beam Therapeutics
BEAM
|
-6.46 | $ 26.43 | 2.15 % | $ 2.61 B | USA |
 |
Fortress Biotech
FBIO
|
74.19 | $ 1.86 | 0.82 % | $ 51.9 M | USA |
 |
Inhibrx
INBX
|
-554.81 | $ 84.71 | 5.52 % | $ 3.99 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-87.31 | $ 3.16 | 5.69 % | $ 146 M | Israel |